In Systemic Sclerosis (SSc), interstitial pulmonary fibrosis is frequent (80%) and is now the leading cause of death. The mortality rate of patients with a forced vital capacity (FVC) <50% of predicted due to SSc pulmonary fibrosis is 40-45% within 10 years of SSc onset. Present evidence suggests that pulmonary fibrosis, which occurs early in the course of SSc, is usually preceded by inflammation which can be detected by examination of cells obtained by bronchoalveolar lavage (BAL). Uncontrolled series suggest that cyclophosphamide (CYC) may stabilize or improve lung function in SSc patients with active alveolitis. We propose to conduct a five- year, l3-center, parallel-group, double-blind, randomized controlled study of oral CYC (1-2 mg/kg/day) versus placebo to assess the efficacy of CYC in stabilizing or improving the course of FVC (as % predicted) in 163 patients with early SSc (within 5 years of clinical disease onset) who are already dyspneic (at least moderate functional impairment and perceived magnitude of task and effort on the Mahler Baseline Dyspnea Index), have an FVC equal to or <85% of predicted and exhibit active alveolitis defined as equal to or >3.0% neutrophils or equal to or >2.0% eosinophils in BAL fluid. Secondarily, we will assess the impact of CYC on quality of life (SF36), functional activity (SSc Health Assessment Questionnaire), dyspnea (Mahler Transition Dyspnea Index) and diffusing capacity for carbon monoxide (DLCO) in these patients. Patients will be recruited for study during the first 3 years (from 6 mos. to 2 yrs, 9 mos) of the 5-year project period. Randomized participants will be treated with study drug for 1 year and followed at 3-month intervals for 2 years. Overall study coordination and data collection, management and analysis will be centralized at UCLA. Proven methods for analyzing time-oriented data employed by the investigators in previous controlled studies of scleroderma will be used to evaluate whether oral CYC (1-2 mg/kg/day) is better than placebo a) in improving or preventing worsening of FVC (the primary outcome variable) and b) in improving or preventing worsening of quality of life, functional ability, breathlessness and DLCO (secondary outcome variables).

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL060606-03
Application #
6389959
Study Section
Clinical Trials Review Committee (CLTR)
Program Officer
Musson, Robert
Project Start
1999-08-10
Project End
2004-06-30
Budget Start
2001-08-15
Budget End
2002-06-30
Support Year
3
Fiscal Year
2001
Total Cost
$255,236
Indirect Cost
Name
University of California Los Angeles
Department
Biostatistics & Other Math Sci
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Namas, Rajaie; Tashkin, Donald P; Furst, Daniel E et al. (2018) Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. Arthritis Care Res (Hoboken) 70:439-444
Volkmann, Elizabeth R; Tashkin, Donald P; Li, Ning et al. (2017) Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol 69:1451-1460
Kafaja, Suzanne; Clements, Philip J; Wilhalme, Holly et al. (2017) Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). Am J Respir Crit Care Med :
Tashkin, Donald P; Volkmann, Elizabeth R; Tseng, Chi-Hong et al. (2016) Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis 75:374-81
Khanna, Dinesh; Nagaraja, Vivek; Tseng, Chi-Hong et al. (2015) Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther 17:372
Volkmann, Elizabeth R; Tashkin, Donald P; Li, Ning et al. (2015) Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease. Rheumatology (Sunnyvale) 5:
Li, Ning; Elashoff, Robert M; Li, Gang et al. (2012) Joint analysis of bivariate longitudinal ordinal outcomes and competing risks survival times with nonparametric distributions for random effects. Stat Med 31:1707-21
Roth, Michael D; Tseng, Chi-Hong; Clements, Philip J et al. (2011) Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 63:2797-808
Hsu, Vivien M; Khanna, Dinesh; Smith, Edwin et al. (2010) Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study. Clin Trials 7:85-9
Goldin, Jonathan; Elashoff, Robert; Kim, Hyun J et al. (2009) Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 136:1333-1340

Showing the most recent 10 out of 16 publications